Of note, this urinary combination biomarker panel showed 82.8% sensitivity for stage 0/I CRC, whereas both serum CEA and CA19-9 showed only 11.1% sensitivity for stage 0/I CRC. The gene discussed is CEACAM5; the disease is colorectal carcinoma.